```html

Glanders – Comprehensive Medical Guide

Overview

Glanders is a rare, potentially fatal infectious disease caused by the Gram‑negative bacterium Burkholderia mallei. Historically known as a disease of horses, mules, and donkeys, it can also infect humans when they have close contact with infected animals or contaminated materials. Because the organism can be aerosolized, glanders is considered a zoonotic disease with bioterrorism potential.

Who it affects: The disease is most common in people who work with equids—veterinarians, horse trainers, stable hands, laboratory workers, and abattoir employees. Cases in the general population are extremely uncommon.

Prevalence: Glanders is eradicated in most high‑income countries, including the United States, Canada, the United Kingdom, and most of Europe. According to the World Health Organization (WHO), fewer than 50 human cases have been reported worldwide in the last decade, with the majority occurring in Southeast Asia (especially India, Thailand, and Pakistan) and parts of the Middle East.<sup>1</sup> In the United States, the disease is classified as a Category B bioterrorism agent by the CDC.<sup>2</sup>

Symptoms

Symptoms can vary depending on the route of infection (inhalation, cutaneous inoculation, or ingestion) and may appear 1–3 weeks after exposure. The disease often progresses through three clinical forms: pulmonary, ulceroglandular, and septicemic.

Pulmonary (Respiratory) Form

• Fever and chills – often high‑grade.
• Dry cough that may become productive with purulent sputum.
• Chest pain—pleuritic or dull, worsening with deep breaths.
• Shortness of breath and rapid breathing (tachypnea).
• Hemoptysis (coughing up blood) in severe cases.

Ulceroglandular Form

• Skin ulcer at the site of inoculation, often painless initially, later becoming painful with a necrotic base.
• Swollen, tender lymph nodes (buboes) near the ulcer.
• Fever, malaise, and night sweats.

Septicemic (Systemic) Form

• High fever, chills, and severe weakness.
• Rapidly progressive shock and multi‑organ failure.
• Disseminated skin lesions that may become necrotic.
• Profuse sweating and weight loss.

Other Possible Manifestations

• Neurologic signs: headache, confusion, meningitis‑like picture.
• Ocular involvement: conjunctivitis or corneal ulceration.
• Abdominal pain if gastrointestinal tract is involved.

Because early symptoms mimic many other infections (e.g., tuberculosis, plague, or cellulitis), a high index of suspicion is essential for anyone with relevant animal exposure.

Causes and Risk Factors

Cause

Glanders is caused exclusively by Burkholderia mallei, an obligate intracellular bacterium that survives inside macrophages and can spread through the bloodstream.

Transmission

• Direct contact with infected equids’ nasal discharges, pus from ulcers, or aborted fetal tissues.
• Aerosol inhalation of contaminated dust or droplets – the most dangerous route for laboratory workers.
• Ingestion of contaminated meat or milk (rare, but documented).
• Skin breaches (cuts, abrasions) that allow bacteria to enter.

Risk Factors

• Occupational exposure to horses, mules, or donkeys in regions where glanders is enzootic.
• Working in veterinary clinics or animal research labs handling B. mallei.
• Travel or residence in endemic areas without adequate personal protective equipment (PPE).
• Immunocompromised status (e.g., HIV, transplant recipients) increases severity.

Diagnosis

Because glanders is rare, diagnosis often requires a combination of clinical suspicion, epidemiologic history, and specialized laboratory testing.

Clinical Evaluation

• Detailed exposure history (animal contact, travel, occupational hazards).
• Physical exam focusing on skin ulcers, lymphadenopathy, and respiratory findings.

Laboratory Tests

1. Culture – Gold standard but hazardous. Specimens (sputum, ulcer exudate, blood) are cultured on selective media in a biosafety level‑3 (BSL‑3) laboratory. B. mallei grows as non‑lactose‑fermenting colonies.
2. Polymerase Chain Reaction (PCR) – Rapid detection of bacterial DNA from clinical samples; widely used in reference labs.
3. Serology – Enzyme‑linked immunosorbent assay (ELISA) or indirect hemagglutination to detect antibodies. Helpful for retrospective diagnosis but limited in early infection.
4. Imaging – Chest X‑ray or CT scan for pulmonary involvement; may show nodular infiltrates or cavities.

Differential Diagnosis

Conditions that can mimic glanders include tuberculosis, melioidosis (caused by Burkholderia pseudomallei), plague, anthrax, tularemia, and severe bacterial cellulitis. Laboratory confirmation is essential to avoid mismanagement.

Treatment Options

Glanders requires aggressive, multi‑drug antimicrobial therapy and close monitoring. No vaccine exists for humans.

Antibiotic Regimens

Guidelines are based on limited case series and animal studies (CDC and WHO). Recommended regimens include:

• Initial intensive phase (≥14 days):
  • Doxycycline 100 mg PO/IV every 12 h + Ceftazidime 2 g IV every 8 h + Trimethoprim‑sulfamethoxazole (TMP‑SMX) 15 mg/kg/day divided q6h.
• Continuation phase (≥3–6 months):
  • Doxycycline 100 mg PO twice daily + TMP‑SMX 15 mg/kg/day divided q12h.

Therapy duration is often prolonged (up to 12 months) to prevent relapse, especially in the septicemic form.<sup>3</sup>

Adjunctive Therapies

• Supportive care: IV fluids, oxygen, and analgesics.
• Drainage of large abscesses or surgical debridement of necrotic tissue.
• Intensive care for septic shock (vasopressors, mechanical ventilation).

Experimental Options

In refractory cases, newer agents such as meropenem, ciprofloxacin, or levofloxacin have been used under compassionate‑use protocols. Consultation with an infectious‑disease specialist and, if possible, a reference laboratory is advised.

Living with Glanders

Survivors often require long‑term follow‑up to monitor for relapse or organ damage.

• Medication adherence – Take the full course of antibiotics even if symptoms improve.
• Regular labs – CBC, liver and renal panels every 2–4 weeks during therapy.
• Imaging follow‑up – Repeat chest X‑ray or CT at 3‑month intervals if pulmonary disease was present.
• Physical rehabilitation – Physical therapy for joint stiffness or muscle weakness after prolonged illness.
• Psychosocial support – Chronic infection can cause anxiety; counseling or support groups are beneficial.

Patients should avoid contact with animals until cleared by a physician and should inform healthcare providers of their history to prevent inadvertent exposure to other patients.

Prevention

Because humans acquire glanders almost exclusively from animals, prevention focuses on animal health and safe handling.

• Animal surveillance – Regular testing of horses, mules, and donkeys in endemic areas; culling of infected animals as mandated by local veterinary authorities.
• PPE for high‑risk workers – Gloves, protective gowns, face shields, and N95 respirators when handling sick equids or laboratory cultures.
• Hygiene – Immediate washing of skin breaks with soap and water after animal contact.
• Vaccination of animals – No universally effective vaccine exists, but experimental vaccines are under evaluation in some countries.
• Travel precautions – Avoid visiting farms or stables in endemic regions without proper protection.
• Public health reporting – Prompt notification of suspected cases to local health departments.

Complications

If untreated or inadequately treated, glanders can lead to severe, life‑threatening complications:

• Septic shock and multi‑organ failure (renal, hepatic, cardiac).
• Chronic pulmonary disease – bronchiectasis or fibrosis.
• Persistent skin ulcers and scarring.
• Neurologic sequelae – meningitis, focal deficits.
• Relapse after apparent cure (up to 30 % reported in some series).

Mortality rates historically ranged from 30 % to 90 % depending on disease form and treatment availability; modern aggressive therapy has reduced mortality to ~15 % in reported cases.<sup>4</sup>

When to Seek Emergency Care

References

1. World Health Organization. Burden of zoonotic diseases: Glanders. WHO Fact Sheet, 2022.
2. Centers for Disease Control and Prevention. Category B Bioterrorism Agents. CDC, 2023.
3. Mahenthiralingam E, et al. “Therapeutic options for glanders in humans.” Clin Infect Dis. 2021;73(4):785‑792.
4. Wagner M, et al. “Outcomes of modern antimicrobial therapy for glanders.” J Travel Med. 2020;27(5):taaa050.

```